The surprising truth about 45% of your asthma patients

What you can do to fix the treatment gap



This content was produced by Australian Doctor Group in partnership with Boehringer Ingelheim.

About 45% of people with asthma have uncontrolled symptoms and for nearly one in five asthma patients, symptoms remain uncontrolled despite regular use of preventers, Australian real-world data shows.1

But how do you identify patients who still have symptoms? And what can you do to bridge the gap between optimal asthma control and actual control?


For further information, samples and resources visit

PBS Information: Restricted benefit. Severe Asthma. Code 11043F. Refer to PBS Schedule for full restricted benefit information.

Please review Product Information before prescribing.
Full Product Information is available at Further Information is available from Boehringer Ingelheim Pty Ltd.

SPIRIVA® RESPIMAT® (tiotropium bromide) solution for inhalation. INDICATIONS: COPD: Long term maintenance treatment of bronchospasm and dyspnoea associated with chronic obstructive pulmonary disease (COPD). Prevention of COPD exacerbations. Asthma: Add-on maintenance bronchodilator treatment in adult patients with asthma, currently treated with the maintenance combination of inhaled corticosteroids (≥800 µg budesonide/day or equivalent) and long-acting ß2 agonists and who experienced one or more severe exacerbations in the previous year. CONTRAINDICATIONS: Hypersensitivity to tiotropium bromide, atropine or its derivatives, or to any of the excipients. PRECAUTIONS: Should not be used for: treatment of acute episodes of bronchospasm, relief of acute symptoms, first-line treatment for asthma. Immediate hypersensitivity reactions, narrow-angle glaucoma, prostatic hyperplasia, bladder-neck obstruction, urinary retention, micturition difficulties, dry mouth, inhalation-induced bronchospasm, recent myocardial infarction (<6 months), unstable or life-threatening cardiac arrhythmia within past year, hospitalisation for heart failure within past year, moderate to severe renal impairment (CrCl ≤ 50 mL/min), pregnancy, lactation, children. Avoid solution or mist entering eyes. INTERACTIONS: Co-administration with anticholinergic drugs. ADVERSE EFFECTS: Common: Dry mouth, usually mild. Others, see full PI. DOSAGE: For oral inhalation. 5 µg tiotropium given as two puffs once daily, at the same time each day. Do not exceed recommended dose. Cartridges to be used only with RESPIMAT inhaler. July 2015.

® Registered trademark. Boehringer Ingelheim Pty Limited. ABN 52 000 452 308. 78 Waterloo Road, North Ryde, NSW 2113. Date of Preparation March 2018. Approval code: AUS/SPI-181014.

Back to top